These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26265036)

  • 61. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes.
    Moreau C; Pautas E; Gouin-Thibault I; Golmard JL; Mahé I; Mulot C; Loriot MA; Siguret V
    J Thromb Haemost; 2011 Apr; 9(4):711-8. PubMed ID: 21255252
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients.
    Cho SM; Lee KY; Choi JR; Lee KA
    Yonsei Med J; 2016 May; 57(3):635-40. PubMed ID: 26996562
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prediction of sensitivity to warfarin based on VKORC1 and CYP2C9 polymorphisms in patients from different places in Colombia.
    Cifuentes RA; Murillo-Rojas J; Avella-Vargas E
    Biomedica; 2016 Mar; 36(1):91-100. PubMed ID: 27622442
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The effect of genetic and nongenetic factors on warfarin dose variability in Qatari population.
    Bader L; Mahfouz A; Kasem M; Mohammed S; Alsaadi S; Abdelsamad O; Elenani R; Soaly E; Elzouki A; Rizk N; Khalifa S; Shahin MH; Cavallari LH; Mraiche F; Elewa H
    Pharmacogenomics J; 2020 Apr; 20(2):277-284. PubMed ID: 31653973
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients.
    Krishna Kumar D; Madhan S; Balachander J; Sai Chandran BV; Thamijarassy B; Adithan C
    Thromb Res; 2013 Apr; 131(4):363-7. PubMed ID: 23473641
    [TBL] [Abstract][Full Text] [Related]  

  • 70. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
    Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
    Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Extremely low therapeutic doses of acenocoumarol in a patient with
    Chaidaroglou A; Kanellopoulou T; Panopoulos G; Stavridis G; Degiannis D
    Pharmacogenomics; 2019 Apr; 20(5):311-317. PubMed ID: 30983536
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients.
    Mushiroda T; Ohnishi Y; Saito S; Takahashi A; Kikuchi Y; Saito S; Shimomura H; Wanibuchi Y; Suzuki T; Kamatani N; Nakamura Y
    J Hum Genet; 2006; 51(3):249-253. PubMed ID: 16432637
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.
    Liu N; Irvin MR; Zhi D; Patki A; Beasley TM; Nickerson DA; Hill CE; Chen J; Kimmel SE; Limdi NA
    Pharmacogenomics; 2017 Jul; 18(11):1059-1073. PubMed ID: 28686080
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Genomewide association analysis of warfarin dose requirements in Middle Eastern and North African populations.
    El Rouby N; Shahin MH; Bader L; Khalifa SI; Elewa H
    Clin Transl Sci; 2022 Feb; 15(2):558-566. PubMed ID: 34729928
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Differential effects of predictors of warfarin dose according to race/color categories in the admixed Brazilian population.
    Suarez-Kurtz G; Struchiner CJ
    Pharmacogenet Genomics; 2017 May; 27(5):210-211. PubMed ID: 28263279
    [No Abstract]   [Full Text] [Related]  

  • 76. Variation in VKORC1 Is Associated with Vascular Dementia.
    Mur J; McCartney DL; Chasman DI; Visscher PM; Muniz-Terrera G; Cox SR; Russ TC; Marioni RE
    J Alzheimers Dis; 2021; 80(3):1329-1337. PubMed ID: 33682710
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients.
    Asiimwe IG; Blockman M; Cohen K; Cupido C; Hutchinson C; Jacobson B; Lamorde M; Morgan J; Mouton JP; Nakagaayi D; Okello E; Schapkaitz E; Sekaggya-Wiltshire C; Semakula JR; Waitt C; Zhang EJ; Jorgensen AL; Pirmohamed M
    Front Pharmacol; 2022; 13():967082. PubMed ID: 36210801
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rare variants discovery by extensive whole-genome sequencing of the Han Chinese population in Taiwan: Applications to cardiovascular medicine.
    Juang JJ; Lu TP; Su MW; Lin CW; Yang JH; Chu HW; Chen CH; Hsiao YW; Lee CY; Chiang LM; Yu QY; Hsiao CK; Chen CJ; Wu PE; Pai CH; Chuang EY; Shen CY
    J Adv Res; 2021 May; 30():147-158. PubMed ID: 34026292
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Association between CYP2C9, VORC1, VDR, and APOE genotypes on warfarin maintenance and response during initial anticoagulation for Chinese patients with heart valve replacement.
    Li X; Wang Z; Liu Z; Xia L; Lyu Q
    Chin Med J (Engl); 2022 Sep; 135(17):2119-2121. PubMed ID: 35202038
    [No Abstract]   [Full Text] [Related]  

  • 80. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma.
    Bailey JN; Loomis SJ; Kang JH; Allingham RR; Gharahkhani P; Khor CC; Burdon KP; Aschard H; Chasman DI; Igo RP; Hysi PG; Glastonbury CA; Ashley-Koch A; Brilliant M; Brown AA; Budenz DL; Buil A; Cheng CY; Choi H; Christen WG; Curhan G; De Vivo I; Fingert JH; Foster PJ; Fuchs C; Gaasterland D; Gaasterland T; Hewitt AW; Hu F; Hunter DJ; Khawaja AP; Lee RK; Li Z; Lichter PR; Mackey DA; McGuffin P; Mitchell P; Moroi SE; Perera SA; Pepper KW; Qi Q; Realini T; Richards JE; Ridker PM; Rimm E; Ritch R; Ritchie M; Schuman JS; Scott WK; Singh K; Sit AJ; Song YE; Tamimi RM; Topouzis F; Viswanathan AC; Verma SS; Vollrath D; Wang JJ; Weisschuh N; Wissinger B; Wollstein G; Wong TY; Yaspan BL; Zack DJ; Zhang K; Study EN; ; Weinreb RN; Pericak-Vance MA; Small K; Hammond CJ; Aung T; Liu Y; Vithana EN; MacGregor S; Craig JE; Kraft P; Howell G; Hauser MA; Pasquale LR; Haines JL; Wiggs JL
    Nat Genet; 2016 Feb; 48(2):189-94. PubMed ID: 26752265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.